Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medarex/Bristol Myers Squibbs’ Ipilimumab Shows Off Long-Term Survival Data At ASCO

This article was originally published in The Pink Sheet Daily

Executive Summary

Data from a separate Phase II combination study also add to hopes for a positive outcome in the ongoing Phase III.

You may also be interested in...



Bristol's Immuno-Oncology Leadership Stake Lies In Ipilimumab's Promise

During Bristol-Myers Squibb's investor day March 4, management's enthusiasm for an important late-stage drug in development for metastatic melanoma, ipilimumab, was palpable. CEO designate Lamberto Andreotti told the room full of analysts and investors that ipilimumab "has the potential to become a paradigm changer in the emerging field of immuno-oncology.

Bristol's Immuno-Oncology Leadership Stake Lies In Ipilimumab's Promise

During Bristol-Myers Squibb's investor day March 4, management's enthusiasm for an important late-stage drug in development for metastatic melanoma, ipilimumab, was palpable. CEO designate Lamberto Andreotti told the room full of analysts and investors that ipilimumab "has the potential to become a paradigm changer in the emerging field of immuno-oncology.

What Medarex Has To Offer At $2.4 Billion

Bristol-Myers Squibb's July 22 offer to buy Medarex for $2.4 billion seems to be a coup for the biotech. While most biotechs are struggling to raise money, Medarex enticed a suitor to pay nearly double its recent stock price

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069589

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel